JP7849948B2 - アデノシン受容体アンタゴニストおよびその使用 - Google Patents

アデノシン受容体アンタゴニストおよびその使用

Info

Publication number
JP7849948B2
JP7849948B2 JP2020570407A JP2020570407A JP7849948B2 JP 7849948 B2 JP7849948 B2 JP 7849948B2 JP 2020570407 A JP2020570407 A JP 2020570407A JP 2020570407 A JP2020570407 A JP 2020570407A JP 7849948 B2 JP7849948 B2 JP 7849948B2
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
compound
alkyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020570407A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021517164A5 (https=
JPWO2019173380A5 (https=
JP2021517164A (ja
Inventor
リュウ，ジウェン
エルゼイン，エルファティフ
Original Assignee
テオン セラピューティクス，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テオン セラピューティクス，インク． filed Critical テオン セラピューティクス，インク．
Publication of JP2021517164A publication Critical patent/JP2021517164A/ja
Publication of JP2021517164A5 publication Critical patent/JP2021517164A5/ja
Publication of JPWO2019173380A5 publication Critical patent/JPWO2019173380A5/ja
Priority to JP2024014959A priority Critical patent/JP2024032976A/ja
Application granted granted Critical
Publication of JP7849948B2 publication Critical patent/JP7849948B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
JP2020570407A 2018-03-05 2019-03-05 アデノシン受容体アンタゴニストおよびその使用 Active JP7849948B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024014959A JP2024032976A (ja) 2018-03-05 2024-02-02 アデノシン受容体アンタゴニストおよびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862638737P 2018-03-05 2018-03-05
US62/638,737 2018-03-05
US201862688088P 2018-06-21 2018-06-21
US62/688,088 2018-06-21
PCT/US2019/020810 WO2019173380A1 (en) 2018-03-05 2019-03-05 Adenosine receptor antagonists and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024014959A Division JP2024032976A (ja) 2018-03-05 2024-02-02 アデノシン受容体アンタゴニストおよびその使用

Publications (4)

Publication Number Publication Date
JP2021517164A JP2021517164A (ja) 2021-07-15
JP2021517164A5 JP2021517164A5 (https=) 2022-04-01
JPWO2019173380A5 JPWO2019173380A5 (https=) 2022-04-01
JP7849948B2 true JP7849948B2 (ja) 2026-04-22

Family

ID=67847428

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020570407A Active JP7849948B2 (ja) 2018-03-05 2019-03-05 アデノシン受容体アンタゴニストおよびその使用
JP2024014959A Withdrawn JP2024032976A (ja) 2018-03-05 2024-02-02 アデノシン受容体アンタゴニストおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024014959A Withdrawn JP2024032976A (ja) 2018-03-05 2024-02-02 アデノシン受容体アンタゴニストおよびその使用

Country Status (12)

Country Link
US (3) US20210040097A1 (https=)
EP (2) EP3762386B1 (https=)
JP (2) JP7849948B2 (https=)
KR (1) KR102754522B1 (https=)
CN (1) CN112218867B (https=)
AU (2) AU2019232736B2 (https=)
BR (1) BR112020018158A2 (https=)
ES (1) ES2975753T3 (https=)
IL (1) IL277144B2 (https=)
MX (1) MX2020009286A (https=)
SG (1) SG11202008611UA (https=)
WO (1) WO2019173380A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2975753T3 (es) 2018-03-05 2024-07-12 Teon Therapeutics Inc Antagonistas del receptor de adenosina y usos de los mismos
WO2022032091A1 (en) * 2020-08-07 2022-02-10 Teon Therapeutics, Inc. Combination therapy with adenosine receptor antagonists
CN116322698A (zh) * 2020-09-04 2023-06-23 泰昂治疗公司 腺苷a2b受体拮抗剂的共晶
WO2022256550A1 (en) 2021-06-04 2022-12-08 Teon Therapeutics, Inc. Crystalline forms of an adenosine a2b receptor antagonist
TW202327612A (zh) * 2021-09-10 2023-07-16 美商天恩治療有限公司 使用腺苷受體拮抗劑之改良療法
EP4554943A1 (en) * 2022-07-14 2025-05-21 Teon Therapeutics, Inc. Adenosine receptor antagonists and uses thereof
WO2026035860A1 (en) 2024-08-07 2026-02-12 Teon Therapeutics, Inc. Formulations of adenosine receptor antagonist

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002511467A (ja) 1998-04-15 2002-04-16 ワーナー−ランバート・カンパニー ベンゾフラニルメチルカルバメートｎｋ１拮抗物質のプロドラッグ
JP2005509036A (ja) 2001-11-09 2005-04-07 シーブイ・セラピューティクス・インコーポレイテッド Ａ２ｂアデノシン受容体アンタゴニスト
JP2005526097A (ja) 2002-03-20 2005-09-02 ブリストル−マイヤーズ　スクイブ　カンパニー フルオロオキシインドールのホスフェートプロドラッグ
JP2013541494A (ja) 2010-06-24 2013-11-14 アルカーメス ファーマ アイルランド リミテッド Ｎｈ酸性化合物のプロドラッグ：エステル、カルボネート、カルバメートおよびホスホネートの誘導体

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466811A (en) * 1994-07-18 1995-11-14 Merck & Co., Inc. Dioxolenylmethyl carbamates pro moieties for amine drugs
US20080318983A1 (en) 2001-11-09 2008-12-25 Rao Kalla A2b adenosine receptor antagonists
US6977300B2 (en) 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7317017B2 (en) 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7125993B2 (en) 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7304070B2 (en) 2001-11-09 2007-12-04 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
DE60322748D1 (de) * 2003-05-06 2008-09-18 Cv Therapeutics Inc Xanthinderivate als a2b-adenosinrezeptorantagonisten
MX2007002437A (es) * 2004-09-01 2007-08-14 Cv Therapeutics Inc Metodo para el sanado de heridas utilizando antagonistas del receptor de adenosina a2b.
EP1799221A1 (en) 2004-10-15 2007-06-27 Cv Therapeutics, Inc. Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists
EP1891070A1 (en) 2005-06-16 2008-02-27 Cv Therapeutics, Inc. Prodrugs of a2b adenosine receptor antagonists
AU2007227021B2 (en) 2006-03-17 2012-12-20 Gilead Sciences, Inc. Method of preventing and treating hepatic disease using A2B adenosine receptor antagonists
WO2008066627A2 (en) 2006-10-24 2008-06-05 Board Of Regents, The University Of Texas System Adenosine signaling in diagnosis, treatment and prevention of priapism and erectile dysfunction
WO2009088518A1 (en) 2008-01-11 2009-07-16 Cv Therapeutics, Inc. A2b adenosine receptor antagonists for the treatment of cancer
EP2268641B1 (en) * 2008-03-26 2014-09-03 Advinus Therapeutics Pvt. Ltd. Heterocyclic compounds as adenosine receptor antagonist
WO2009157938A1 (en) 2008-06-26 2009-12-30 Cv Therapeutics, Inc. A2b adenosine receptor antagonists for treating cancer
BR112012032766A2 (pt) 2010-06-30 2019-09-24 Gilead Sciences Inc uso de antagonistas do receptor de adenosina a2b para o tratamento da hipertensão pulmonar
CN103261200B (zh) * 2010-09-13 2016-03-30 阿迪维纳斯疗法有限公司 作为a2b腺苷受体拮抗剂的前药的嘌呤化合物、它们的制备方法及医药用途
AR085942A1 (es) * 2011-04-07 2013-11-06 Gilead Sciences Inc Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio
WO2012170209A2 (en) * 2011-05-23 2012-12-13 Nectid, Inc. Benzofuran-2 carboxamide compounds
US10117868B2 (en) 2011-10-25 2018-11-06 Case Western Reserve University Systems pharmacology for treating ocular disorders
CN111093669A (zh) 2017-08-14 2020-05-01 法斯瑞斯公司 用于治疗癌症的腺苷受体拮抗剂的微颗粒制剂
CN111741752A (zh) 2017-12-19 2020-10-02 Gpcr治疗公司 Gpcr异聚体抑制剂及其用途
ES2975753T3 (es) 2018-03-05 2024-07-12 Teon Therapeutics Inc Antagonistas del receptor de adenosina y usos de los mismos

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002511467A (ja) 1998-04-15 2002-04-16 ワーナー−ランバート・カンパニー ベンゾフラニルメチルカルバメートｎｋ１拮抗物質のプロドラッグ
JP2005509036A (ja) 2001-11-09 2005-04-07 シーブイ・セラピューティクス・インコーポレイテッド Ａ２ｂアデノシン受容体アンタゴニスト
JP2005526097A (ja) 2002-03-20 2005-09-02 ブリストル−マイヤーズ　スクイブ　カンパニー フルオロオキシインドールのホスフェートプロドラッグ
JP2013541494A (ja) 2010-06-24 2013-11-14 アルカーメス ファーマ アイルランド リミテッド Ｎｈ酸性化合物のプロドラッグ：エステル、カルボネート、カルバメートおよびホスホネートの誘導体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AAPS PharmSciTech, 2012, Vol. 13, pp. 853-862

Also Published As

Publication number Publication date
AU2019232736B2 (en) 2024-05-02
ES2975753T3 (es) 2024-07-12
KR102754522B1 (ko) 2025-01-13
US20210163483A1 (en) 2021-06-03
CN112218867B (zh) 2023-11-21
US20210040097A1 (en) 2021-02-11
AU2019232736A1 (en) 2020-10-08
IL277144B1 (en) 2024-02-01
JP2024032976A (ja) 2024-03-12
WO2019173380A1 (en) 2019-09-12
EP4364727A3 (en) 2024-05-15
AU2024204483B2 (en) 2026-04-02
EP3762386A1 (en) 2021-01-13
KR20200132901A (ko) 2020-11-25
IL277144B2 (en) 2024-06-01
US11124515B2 (en) 2021-09-21
EP3762386A4 (en) 2021-11-24
SG11202008611UA (en) 2020-10-29
CA3093234A1 (en) 2019-09-12
BR112020018158A2 (pt) 2021-02-02
JP2021517164A (ja) 2021-07-15
MX2020009286A (es) 2020-12-11
IL277144A (en) 2020-10-29
CN112218867A (zh) 2021-01-12
EP4364727A2 (en) 2024-05-08
AU2024204483A1 (en) 2024-07-18
US20220056033A1 (en) 2022-02-24
EP3762386B1 (en) 2024-01-24

Similar Documents

Publication Publication Date Title
JP7849948B2 (ja) アデノシン受容体アンタゴニストおよびその使用
TWI473613B (zh) 用作肥大細胞類胰蛋白酶抑制劑之〔４－（５－胺基甲基－２－氟－苯基）－六氫吡啶－１－基〕－〔７－氟－１－（２－甲氧基－乙基）－４－三氟甲氧基－１ｈ－吲哚－３－基〕－甲酮
JP6602902B2 (ja) 脾臓チロシンキナーゼｉ（ｓｙｋ）阻害剤としての２−（２−アミノシクロヘキシル）アミノピリミジン−５−カルボキサミド類
TW202003466A (zh) 人類整合素α４β７拮抗劑
JP2026074199A (ja) アデノシン受容体アンタゴニストおよびその使用
WO2019232662A1 (zh) 一类具有抗癌活性的吲嗪类化合物及其衍生物
HK40108164A (en) Adenosine receptor antagonists and uses thereof
CA3093234C (en) Adenosine receptor antagonists and uses thereof
HK40041747B (en) Adenosine receptor antagonists and uses thereof
HK40041747A (en) Adenosine receptor antagonists and uses thereof
EA043897B1 (ru) Антагонисты аденозиновых рецепторов и их применения
JP2021532069A (ja) 新規な気管支拡張性ヘテロ結合アミド
TWI845843B (zh) 新型吡嗪化合物
JP2645114B2 (ja) ロダニン誘導体
WO2025096782A1 (en) Fluorinated cannabinoid compositions and methods thereof
WO2013083541A1 (en) (4-mercapto-piperidin-4-yl)-aminoacetic acid derivatives, pharmaceutical compositions and uses thereof
TW202328073A (zh) Ｅｐ４拮抗劑化合物及其鹽、多晶型及其製備方法和用途
JPS63275581A (ja) ４−（３−クマリニル）−チアゾール誘導体、その製造法及び該誘導体を含有する医薬
JPS63275588A (ja) ベンゾピラン〔４，３−ｄ〕−チアゾール誘導体、その製造方法及び該誘導体を含有する医薬
HK1189888A (en) Intermediates for preparing indole benzylamine compound
HK1156598B (en) [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1h-indol-3-yl]-methanone as an inhibitor of mast cell tryptase
JPS6230712A (ja) 抗血栓剤
JPH0153859B2 (https=)

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20220303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220304

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20220304

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230704

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240202

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240311

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240607

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260410